文献速递类风湿关节炎

欧洲药品管理局风险最小化措施对英国JAK抑制剂处方与使用方式的潜在影响

Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于BSRBR-RA队列中2017年2月13日至2022年5月31日首次启用JAK抑制剂(JAKi)的1341例类风湿关节炎患者,80%(1075例)符合至少一条EMA风险标准;其中49%(529例)将JAKi作为第一或第二类生物/靶向合成DMARD,28%(299例)已用过至少3类bDMARD。作者认为约三分之一高风险患者替代选择非常有限,其余患者可能存有合适替代方案,或需重新评估治疗适宜性。

要点

  • 在EMA措施发布前启用JAKi的1341例RA患者中,80%(1075例)符合至少一条EMA风险标准。
  • 符合风险标准者中,49%(529例)以JAKi作为第一或第二类b/tsDMARD。
  • 符合风险标准者中,28%(299例)此前已使用至少3类bDMARD。

核心结论

  • 在EMA发布风险最小化措施前已启用JAKi的RA患者中,五分之四被视为「高风险」,仅在没有合适替代方案时才建议处方JAKi。
  • 符合风险标准者中近三分之一已用过至少3类bDMARD,替代治疗非常有限;其余患者可能存有合适替代方案。
  • 作者认为对以JAKi作为第一或第二类b/tsDMARD等的患者,或需重新评估其治疗适宜性。

研究设计与样本

  • 分析纳入BSRBR-RA大型全国队列研究中2017年2月13日至2022年5月31日首次启用JAKi的RA患者。
  • 报告符合EMA风险标准的患者百分比,并描述高风险患者既往使用过的不同bDMARD类别数。

主要发现

  • 共纳入1341例患者,80%(N=1075)符合至少一条EMA风险标准。
  • 符合至少一条风险标准的患者中,529例(49%)将JAKi作为第一或第二类b/tsDMARD。
  • 符合至少一条风险标准的患者中,299例(28%)此前已使用至少3类bDMARD。

关键数值与推荐

  • EMA风险最小化措施将JAKi处方限制于特定高风险患者,除非没有合适替代方案。
  • 符合至少一条EMA风险标准:80%(1075/1341)。
  • 符合风险标准者中JAKi作为第一或第二类b/tsDMARD:49%(529例)。
  • 符合风险标准者中既往至少3类bDMARD:28%(299例)。

临床怎么用

  • 作者认为已用过至少3类bDMARD的高风险患者替代治疗非常有限。
  • 作者认为其余高风险患者可能存有合适替代方案,尤其是以JAKi作为第一或第二类b/tsDMARD者。
  • 作者提出对上述患者或需重新评估其治疗适宜性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Janus kinase inhibitors (JAKis) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) effectively treat rheumatoid arthritis (RA). However, due to safety concerns, the European Medicines Agency (EMA) published risk-minimization measures limiting JAKi prescription to certain at-risk patients unless no suitable alternative is available. This analysis included patients who had started their first-ever JAKi (before EMA measures were published) in a large national cohort study to investigate the potential impact of these measures on JAKi prescribing and utilization in the UK. METHOD: RA patients starting first-ever JAKi therapy in BSRBR-RA between 13 February 2017 and 31 May 2022 were included. The percentages of patients meeting the EMA risk criteria were presented. For the at-risk patients, their previous numbers of distinct biologic (b) DMARD classes prescribed were described. RESULT: A total of 1341 patients were included, and 80% (N = 1075) met ≥1 EMA risk criterion. Of those who met ≥1 risk criterion, 529 patients (49%) had received JAKi as their first or second b/tsDMARD class, whereas 299 (28%) had received ≥3 prior bDMARD classes. CONCLUSION: Four-fifths of RA patients who had commenced a JAKi before the EMA advisory were considered 'at-risk', with prescribing only advised if there was no suitable alternative. Almost a third of those patients had already received ≥3 bDMARDs classes, and alternative therapies would be very limited for them; however, suitable alternatives might have existed for the remaining proportion, especially for those who received a JAKi as their first or second b/tsDMARD, and re-evaluation of the suitability of their treatment may be needed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tian Z, Kearsley-Fleet L, Galloway J, et al. Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK. Rheumatology (Oxford). 2025. PMID: 38748995. doi:10.1093/rheumatology/keae279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。